Ratings by Jefferies (Andrew Tsai)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/11/2026 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 5/14/2026 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2026 | Praxis Precision Medicines Inc. | PRAX | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2026 | Compass Pathways | CMPS | New Coverage | Buy (N/A) |
9.06 (13.50) |
49.01% | Details | |
| 4/15/2026 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 4/14/2026 | Praxis Precision Medicines Inc. | PRAX | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2026 | Bright Minds Biosciences Inc. | DRUG | New Coverage | Buy (N/A) |
85.91 (67.43) |
-21.51% | Details | |
| 4/1/2026 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2026 | Annexon Biosciences | ANNX | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2026 | Savara | SVRA | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2026 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2026 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 3/23/2026 | Supernus Pharmaceuticals | SUPN | Maintain | Buy (N/A) |
|
Details | ||
| 3/19/2026 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2026 | Alto Neuroscience | ANRO | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2026 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2026 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2026 | Dyne Therapeutics | DYN | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2026 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2026 | atai Life Sciences N.V | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2026 | Silence Therapeutics | SLN | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2026 | Helus Pharma | HELP | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2026 | Moderna | MRNA | Maintain | Hold (N/A) |
|
Details | ||
| 3/3/2026 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2026 | Helus Pharma | HELP | New Coverage | Buy (N/A) |
6.77 (6.42) |
-5.17% | Details | |
| 1/30/2026 | Definium Therapeutics Inc | DFTX | New Coverage | Buy (N/A) |
16.84 (43.84) |
160.33% | Details | |
| 1/5/2026 | Moderna | MRNA | Maintain | Hold (N/A) |
|
Details | ||
| 12/17/2025 | VistaGen Therapeutics | VTGN | Downgrade | Hold (Buy) |
4.36 (0.25) |
-94.27% | Details | |
| 12/12/2025 | Moderna | MRNA | New Coverage | Hold (N/A) |
29.03 (71.89) |
147.64% | Details | |
| 12/3/2025 | MapLight Therapeutics | MPLT | Maintain | Buy (N/A) |
|
Details | ||
| 11/21/2025 | MapLight Therapeutics | MPLT | New Coverage | Buy (N/A) |
14.60 (35.33) |
141.99% | Details | |
| 10/8/2025 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2025 | Biogen | BIIB | New Coverage | Buy (N/A) |
139.31 (210.47) |
51.08% | Details | |
| 9/10/2025 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2025 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Hold (N/A) |
|
Details | ||
| 8/6/2025 | Lexicon Pharmaceuticals | LXRX | Maintain | Hold (N/A) |
|
Details | ||
| 7/24/2025 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 7/18/2025 | Stoke Therapeutics | STOK | New Coverage | Buy (N/A) |
11.90 (32.74) |
175.13% | Details | |
| 7/14/2025 | BridgeBio Pharma | BBIO | New Coverage | Buy (N/A) |
46.27 (74.95) |
61.98% | Details | |
| 5/28/2025 | Rocket Pharmaceuticals | RCKT | Downgrade | Hold (Buy) |
6.27 (3.43) |
-45.3% | Details | |
| 5/27/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Buy (N/A) |
|
Details | ||
| 5/22/2025 | Vigil Neuroscience Inc | VIGL | Downgrade | Hold (Buy) |
2.31 (8.05) |
248.48% | Details | |
| 4/7/2025 | Axsome Therapeutics | AXSM | New Coverage | Buy (N/A) |
107.89 (239.57) |
122.05% | Details | |
| 12/18/2024 | Rocket Pharmaceuticals | RCKT | New Coverage | Buy (N/A) |
11.76 (6.27) |
-46.68% | Details | |
| 11/14/2024 | Marinus Pharmaceuticals | MRNS | Maintain | Hold (N/A) |
|
Details | ||
| 10/24/2024 | Marinus Pharmaceuticals | MRNS | Downgrade | Hold (Buy) |
1.69 (0.55) |
-67.46% | Details | |
| 10/21/2024 | Sarepta Therapeutics | SRPT | New Coverage | Buy (N/A) |
124.25 (18.17) |
-85.38% | Details | |
| 9/17/2024 | Relmada Therapeutics Inc | RLMD | Upgrade | Buy (Hold) |
3.09 (4.15) |
34.3% | Details | |
| 8/13/2024 | atai Life Sciences N.V | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 7/2/2024 | Rapport Therapeutics | RAPP | New Coverage | Buy (N/A) |
23.26 (40.03) |
72.1% | Details | |
| 5/7/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 4/18/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | Alto Neuroscience | ANRO | New Coverage | Buy (N/A) |
13.72 (25.32) |
84.55% | Details | |
| 2/8/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2024 | Vertex | VRTX | Maintain | Hold (Hold) |
|
Details | ||
| 12/7/2023 | VistaGen Therapeutics | VTGN | Upgrade | Buy (Hold) |
4.29 (4.36) |
1.63% | Details | |
| 10/4/2023 | POINT Biopharma Global Inc. | PNT | Downgrade | Hold (Buy) |
6.68 (12.50) |
87.13% | Details | |
| 7/20/2023 | POINT Biopharma Global Inc. | PNT | New Coverage | Buy (N/A) |
9.24 (12.50) |
35.28% | Details | |
| 5/29/2023 | Annexon Biosciences | ANNX | Maintain | Buy (N/A) |
|
Details | ||
| 5/16/2023 | Savara | SVRA | New Coverage | Buy (N/A) |
1.99 (6.05) |
204.02% | Details | |
| 3/7/2023 | Lexicon Pharmaceuticals | LXRX | New Coverage | Hold (N/A) |
2.68 (2.39) |
-10.82% | Details | |
| 12/19/2022 | Vertex | VRTX | Downgrade | Hold (Buy) |
308.40 (459.92) |
49.13% | Details | |
| 11/9/2022 | Marinus Pharmaceuticals | MRNS | Maintain | Buy (N/A) |
|
Details | ||
| 7/22/2022 | VistaGen Therapeutics | VTGN | Downgrade | Hold (Buy) |
1.07 (0.25) |
-76.64% | Details | |
| 7/6/2022 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2022 | Athira Pharma | ATHA | Downgrade | Hold (Buy) |
8.45 (6.75) |
-20.12% | Details | |
| 6/21/2022 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 5/31/2022 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2022 | atai Life Sciences N.V | ATAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/1/2022 | Vigil Neuroscience Inc | VIGL | New Coverage | Buy (N/A) |
14.65 (2.31) |
-84.23% | Details | |
| 1/25/2022 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 10/4/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 9/20/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 9/1/2021 | atai Life Sciences N.V | ATAI | New Coverage | Buy (N/A) |
15.93 (4.91) |
-69.18% | Details | |
| 8/30/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2021 | VistaGen Therapeutics | VTGN | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2021 | Minerva Neurosciences | NERV | New Coverage | Hold (N/A) |
2.41 (5.35) |
121.99% | Details | |
| 6/8/2021 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2021 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 4/19/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 4/16/2021 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 4/1/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2021 | Marinus Pharmaceuticals | MRNS | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/18/2021 | VistaGen Therapeuticsen Therapeutics | VTGN | New Coverage | Buy (N/A) |
1.99 (0.25) |
-87.44% | Details | |
| 12/21/2020 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 11/6/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 10/13/2020 | Athira Pharma | ATHA | New Coverage | Buy (N/A) |
16.81 (6.75) |
-59.85% | Details | |
| 9/15/2020 | Marinus Pharmaceuticals | MRNS | Maintain | Buy (N/A) |
|
Details | ||
| 5/31/2020 | Xenon Pharmaceuticals | XENE | New Coverage | Buy (N/A) |
12.70 (60.17) |
373.78% | Details | |
| 1/27/2020 | Relmada Therapeutics Inc | RLMD | New Coverage | Buy (N/A) |
40.66 (3.09) |
-92.4% | Details | |
| 9/16/2019 | Zynerba Pharmaceuticals | ZYNE | New Coverage | Hold (N/A) |
12.19 (1.30) |
-89.34% | Details | |
| 8/12/2019 | Intra-Cellular Therapies | ITCI | New Coverage | Buy (N/A) |
9.23 (131.87) |
1328.71% | Details | |
| 7/23/2019 | Marinus Pharmaceuticals | MRNS | Maintain | Buy (N/A) |
|
Details | ||
| 4/25/2019 | Sage Therapeutics | SAGE | New Coverage | Buy (N/A) |
166.98 (8.68) |
-94.8% | Details | |
| 3/5/2019 | Marinus Pharmaceuticals | MRNS | New Coverage | Buy (N/A) |
3.49 (1.69) |
-51.58% | Details |
